The new funds will allow the company to test its multi-node PI3K treatment approach in a new endometrial cancer trial.
The FDA has accepted Pharming Group’s supplemental new drug application for leniolisib in treating activated phosphoinositide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback